BIO-TECHNE Corp Stock Nasdaq
Equities
US8783771004
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 23 | Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe | MT |
Apr. 18 | Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85 | MT |
Financials (USD)
Sales 2024 * | 1.15B | Sales 2025 * | 1.25B | Capitalization | 9.85B |
---|---|---|---|---|---|
Net income 2024 * | 179M | Net income 2025 * | 229M | EV / Sales 2024 * | 8.75 x |
Net Debt 2024 * | 187M | Net cash position 2025 * | 10.85M | EV / Sales 2025 * | 7.9 x |
P/E ratio 2024 * |
56.5
x | P/E ratio 2025 * |
44.1
x | Employees | - |
Yield 2024 * |
0.51% | Yield 2025 * |
0.51% | Free-Float | 99.02% |
Latest transcript on BIO-TECHNE Corp
Managers | Title | Age | Since |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 18-04-29 |
James Hippel
DFI | Director of Finance/CFO | 53 | 14-03-31 |
Matthew McManus
COO | Chief Operating Officer | 55 | Jan. 07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 02-12-31 | |
Randolph Steer
BRD | Director/Board Member | 74 | 89-12-31 |
Joseph Keegan
BRD | Director/Board Member | 71 | 17-10-25 |
1st Jan change | Capi. | |
---|---|---|
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |